BALAXI PHARMACEUTICALS LIMITED (BALAXI): Financials & Fundamentals History

Share price

Closing priceAdjusted for splits and bonus issues.

3M1Y3YAll

₹22.66 latest close · −4.3% over the last 90 sessions

₹22.66 month-end · −38.3% over 12 months

₹22.66 month-end · −72.9% over 3 years

₹22.66 month-end · +45.7% since Jun '19

52-week range ₹15.20 to ₹43.85 · 1-year volatility 48.0%

Was the rally earned?

1 year3 years5 years

-38%share price, 1 yearEarnings-driven

Mostly earnings.

Per-share earnings took off 161 points, while the multiple moved less (P/E 10.7x to 50.4x).
The share count barely moved.

Net profit growth-161 ptsNet profit fell about 87%, which lowers the price.

P/E change+123 ptsThe P/E rose from 10.7x to 50.4x, which lifts the price.

Share count change0 ptsShare count was little changed. More shares would count against the price.

-73%share price, 3 yearsEarnings-driven

Mostly earnings.

Per-share earnings took off 167 points, while the multiple moved less (P/E 9.3x to 50.4x).
The share count rose 8%.

Net profit growth-163 ptsNet profit fell about 95%, which lowers the price.

P/E change+95 ptsThe P/E rose from 9.3x to 50.4x, which lifts the price.

Share count change-4 ptsShare count rose 8%, which lowers the price.

-79%share price, 5 yearsEarnings-driven

Mostly earnings.

Per-share earnings took off 145 points, while the multiple moved less (P/E 13.8x to 50.4x).
The share count rose 11%.

Net profit growth-139 ptsNet profit fell about 93%, which lowers the price.

P/E change+66 ptsThe P/E rose from 13.8x to 50.4x, which lifts the price.

Share count change-5 ptsShare count rose 11%, which lowers the price.

What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-92.5%not yet recovered

1-year volatility48.0%annualised

Drawdown from peak

Largest drawdowns

-92.5% (2020-10 peak to 2026-03 low, not yet recovered)

-53.1% (2019-05 peak to 2019-07 low, recovered 2020-07)

-26.5% (2020-09 peak to 2020-09 low, recovered 2020-10)

Is it expensive against its own past and its peers?

50.4xP/E todayNear its historic high

Against its own history84th percentile

CheapestMedian 12.4xDearest

Usual range 9.4x to 87.3x since 2019-06.

Against Health Technology50.4x vs 37.0x

This company

50.4x

Sector median

37.0x

36% above the Health Technology median.

P/EP/BP/S

P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

ROCE16th▼ 27 pts vs a year ago
Op. margin15th▼ 6 pts vs a year ago
Revenue growth10th▼ 76 pts vs a year ago
EPS growth8thflat vs a year ago
Debt/equity ↓51st▲ 3 pts vs a year ago
Cash cycle ↓12thflat vs a year ago
P/E ↓32nd▼ 61 pts vs a year ago
12M momentum3rdflat vs a year ago

Rank history

ROCE

Op. margin

Revenue growth

EPS growth

Debt/equity ↓

Cash cycle ↓

P/E ↓

12M momentum

Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26

Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~1%annual earnings growth implied by the price

At a P/E of 5.2x, the price would imply about 0.7%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Below the ₹1,000 cr market-cap floor used for the lists.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov: ₹22.66
P/E: 50.4x
ROCE: 3.0%
Market Cap: ₹125 cr
Revenue (TTM): ₹280 cr
P/S: 0.4x
P/B: 0.5x
ROE: 1.0%
Operating Margin: 5.8%
Debt / Equity: 0.2x
Promoter Holding: 66.0%
12M Momentum: -38.3%

52-week range

₹15.20₹43.85

26% of the way from its 52-week low to its high

Price risk

1Y volatility

48.0%

Beta vs sector

1-year daily

0.64

Balance sheet & cash

Interest cover

operating profit ÷ interest

2.8x

Cash from profit, 3Y

operating cash flow ÷ net profit

-1.42x

low

Share count, 1Y

unchanged

Are profits backed by cash?

3 of 7checks within range3 beyond a threshold

Other income reliance56%Beyond threshold

Other income as a share of pre-tax profit (trailing twelve months): 55.9%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate28%Within range

Median quarterly effective tax rate over about 2.5 years: 27.8%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion-1.42xBeyond threshold

Operating cash flow divided by net profit over the last three fiscal years: -1.42x (cash from operations ₹-34 cr, net profit ₹24 cr). Bands: 0.8x and above, 0.5x to 0.8x, below 0.5x.

Free cash flow2 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 2. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+100 daysBeyond threshold

Debtor days are above the median of the previous three fiscal years by 100 days (184 vs 84). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress0% of fixed assetsWithin range

Capital work-in-progress is 0% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days-31 days / 2 yrsWithin range

Days payable changed by -31 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

Over 3 years, FIIs trimmed 18.6 pts; promoters trimmed 5.2 pts; DIIs added 2.5 pts.
The number of shareholders rose from 5,047 to 14,682 (+191%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change

Promoters71.2%66.0%-5.2 pts

FIIs18.6%0.0%-18.6 pts

DIIs0.0%2.6%+2.5 pts

Public and others10.2%31.4%+21.3 pts

Number of shareholders

14,682shareholders+191% since Sep '23

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+2.3%typical 12-month return vs the marketAbove the base rate

We found 50 past situations where a non-financial company looked like BALAXI PHARMACEUTICALS LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
Over the following 12 months the middle half of them returned −19% to +38% vs the market, against −7% for all non-financial companies in the same months.
The analogs' median sat above that base rate (gap +8.8%, 80% range +0.1% to +22.1%), but the matches cluster in only 6 distinct 12-month windows.

Where the 50 outcomes landed

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 3 beyond the range shown, drawn at the edge

Similar setups' median

+2.3%

All companies' median

−6.5%

Beat the market

54% vs 43%

50 past situations · 50 companies · 34 months · 2020–2025

The closest matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ISFT Retail Trade	Jan 2021	48x	2%	−21%	−29%	+125%
HTMEDIA Consumer Services	May 2020	—	3%	−69%	−69%	+40%
ORIENTBELL Producer Manufacturing	May 2025	72x	1%	−32%	−43%	+34%
BIRLACABLE Producer Manufacturing	Jul 2025	104x	5%	−43%	−44%	+15%
VASCONEQ Industrial Services	May 2020	19x	3%	−55%	−60%	+39%

Show the other 3 matches

Company	When	P/E	ROCE	12M mom.	Drawdown	Next 12 months
ALKALI Process Industries	Aug 2024	103x	6%	−4%	−28%	−20%
RUCHIRA Process Industries	Aug 2021	37x	4%	+30%	−23%	+72%
INCREDIBLE Non-Energy Minerals	Mar 2021	87x	4%	+55%	−42%	−11%

How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and interest cover. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to BALAXI PHARMACEUTICALS LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

Feature	Weight	Non-financial	Financial
P/E	1	yes	yes
P/S	1	yes	—
P/B	1	—	yes
ROCE	1	yes	—
operating margin	1	yes	—
ROE	1	—	yes
debt/equity	0.75	yes	—
interest cover	0.5	yes	—
revenue growth	0.75	yes	yes
12-month momentum	1	yes	yes
drawdown from 12-month high	0.75	yes	yes
size	0.75	yes	yes
volatility	0.5	yes	yes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What changed?

30 events since Jun '20

2026
JunValuationP/E crossed above the 90th percentile of its own history to date (92.0x).
JunPeer rankSlipped to the bottom quartile of Health Technology on ROCE (from the 3rd quartile).
MarPriceFell 92% from the Oct 2020 peak to the Mar 2026 low.
JanValuationP/E fell below the 10th percentile of its own history to date (9.3x).
2025
SepInstitutionsFII + DII holding fell 7.6 pts over 2 quarters to 8.9%.
SepPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).
JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
MarPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 3rd quartile).

Show 22 earlier events

2024
DecPeer rankSlipped to the bottom quartile of Health Technology on EPS growth (from the 3rd quartile).
NovValuationP/E fell below the 10th percentile of its own history to date (9.5x).
SepResultsEPS (TTM) turned positive.
SepPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
JunPromoterPromoter holding fell 4.4 pts to 66.9%.
JunResultsEPS (TTM) turned negative.
JunPeer rankSlipped to the 2nd quartile of Health Technology on ROCE (from the top quartile).
JunSharesShare count is up 10.0% over 12 months.
2023
AugValuationP/E fell below the 10th percentile of its own history to date (10.2x).
JunResultsYear-on-year EPS growth turned negative.
JunPeer rankSlipped to the 2nd quartile of Health Technology on EPS growth (from the top quartile).
JunDividendDividend payout cut from 1% to 0% of profit.
2022
JunResultsRevenue (TTM) reached a new high of ₹279 cr.
JunDividendStarted paying a dividend (payout 1% of profit).
FebValuationP/E fell below the 10th percentile of its own history to date (11.0x).
2021
JunResultsYear-on-year EPS growth turned positive.
JunPeer rankMoved into the top quartile of Health Technology on EPS growth (from the 3rd quartile).
2020
OctPriceRegained the 2020-09 peak, 1 month after the low.
SepPriceFell 26% from the Sep 2020 peak to the Sep 2020 low.
JulPriceRegained the 2019-05 peak, 12 months after the low.
JunResultsRevenue (TTM) reached a new high of ₹46 cr.
JunSharesShare count is up 200.0% over 12 months.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history90 months · 2019-06 to 2026-11

Month	P/E	Revenue (TTM)	ROE	ROCE	Debt / Equity
2026-11	50.4x	₹280 cr	1.0%	3.0%	0.2x
2026-10	42.6x	₹280 cr	1.0%	3.0%	0.2x
2026-09	50.6x	₹280 cr	1.0%	3.0%	0.2x
2026-08	85.9x	₹270 cr	0.6%	3.0%	0.2x
2026-07	91.9x	₹270 cr	0.6%	3.0%	0.2x
2026-06	92.0x	₹270 cr	0.6%	3.0%	0.2x
2026-05	15.2x	₹276 cr	4.1%	13.0%	0.2x
2026-04	15.5x	₹276 cr	4.1%	13.0%	0.2x
2026-03	9.1x	₹276 cr	4.1%	13.0%	0.2x
2026-02	7.5x	₹276 cr	6.3%	13.0%	0.2x
2026-01	9.3x	₹276 cr	6.3%	13.0%	0.2x
2025-12	10.2x	₹276 cr	6.3%	13.0%	0.2x
2025-11	10.7x	₹298 cr	8.1%	13.0%	0.2x
2025-10	12.6x	₹298 cr	8.1%	13.0%	0.2x
2025-09	12.8x	₹298 cr	8.1%	13.0%	0.2x
2025-08	10.1x	₹293 cr	10.8%	13.0%	0.2x
2025-07	10.5x	₹293 cr	10.8%	13.0%	0.2x
2025-06	11.0x	₹293 cr	10.8%	13.0%	0.2x
2025-05	10.0x	₹276 cr	13.6%	21.0%	0.1x
2025-04	11.1x	₹276 cr	13.6%	21.0%	0.1x
2025-03	12.8x	₹276 cr	13.6%	21.0%	0.1x
2025-02	8.0x	₹264 cr	17.7%	21.0%	0.1x
2025-01	10.2x	₹264 cr	17.7%	21.0%	0.1x
2024-12	10.9x	₹264 cr	17.7%	21.0%	0.1x
2024-11	9.5x	₹241 cr	22.6%	21.0%	0.1x
2024-10	10.4x	₹241 cr	22.6%	21.0%	0.1x
2024-09	12.3x	₹241 cr	22.6%	21.0%	0.1x
2024-08	—	₹241 cr	-1.6%	21.0%	0.1x
2024-07	—	₹241 cr	-1.6%	21.0%	0.1x
2024-06	—	₹241 cr	-1.6%	21.0%	0.1x
2024-05	13.2x	₹336 cr	25.1%	37.0%	0.1x
2024-04	13.5x	₹336 cr	25.1%	37.0%	0.1x
2024-03	11.0x	₹336 cr	25.1%	37.0%	0.1x
2024-02	13.6x	₹336 cr	25.1%	37.0%	0.1x
2024-01	9.8x	₹336 cr	25.1%	37.0%	0.1x
2023-12	9.6x	₹336 cr	25.1%	37.0%	0.1x
2023-11	9.3x	₹336 cr	25.1%	37.0%	0.1x
2023-10	8.9x	₹336 cr	25.1%	37.0%	0.1x
2023-09	9.9x	₹336 cr	25.1%	37.0%	0.1x
2023-08	10.2x	₹336 cr	25.1%	37.0%	0.1x
2023-07	11.4x	₹336 cr	25.1%	37.0%	0.1x
2023-06	11.7x	₹336 cr	25.1%	37.0%	0.1x
2023-05	11.4x	₹279 cr	42.5%	60.0%	0.0x
2023-04	11.2x	₹279 cr	42.5%	60.0%	0.0x
2023-03	11.1x	₹279 cr	42.5%	60.0%	0.0x
2023-02	11.3x	₹279 cr	42.5%	60.0%	0.0x
2023-01	11.5x	₹279 cr	42.5%	60.0%	0.0x
2022-12	12.7x	₹279 cr	42.5%	60.0%	0.0x
2022-11	12.4x	₹279 cr	42.5%	60.0%	0.0x
2022-10	12.6x	₹279 cr	42.5%	60.0%	0.0x
2022-09	12.8x	₹279 cr	42.5%	60.0%	0.0x
2022-08	12.1x	₹279 cr	42.5%	60.0%	0.0x
2022-07	8.2x	₹279 cr	42.5%	60.0%	0.0x
2022-06	7.4x	₹279 cr	42.5%	60.0%	0.0x
2022-05	10.9x	₹231 cr	58.5%	93.0%	0.1x
2022-04	11.6x	₹231 cr	58.5%	93.0%	0.1x
2022-03	9.2x	₹231 cr	58.5%	93.0%	0.1x
2022-02	11.0x	₹231 cr	58.5%	93.0%	0.1x
2022-01	12.7x	₹231 cr	58.5%	93.0%	0.1x
2021-12	13.4x	₹231 cr	58.5%	93.0%	0.1x
2021-11	13.8x	₹231 cr	58.5%	93.0%	0.1x
2021-10	14.6x	₹231 cr	58.5%	93.0%	0.1x
2021-09	15.0x	₹231 cr	58.5%	93.0%	0.1x
2021-08	14.2x	₹231 cr	58.5%	93.0%	0.1x
2021-07	15.4x	₹231 cr	58.5%	93.0%	0.1x
2021-06	15.4x	₹231 cr	58.5%	93.0%	0.1x
2021-05	110.6x	₹46 cr	21.4%	57.0%	0.0x
2021-04	95.9x	₹46 cr	21.4%	57.0%	0.0x
2021-03	86.0x	₹46 cr	21.4%	57.0%	0.0x
2021-02	88.6x	₹46 cr	21.4%	57.0%	0.0x
2021-01	86.4x	₹46 cr	21.4%	57.0%	0.0x
2020-12	106.6x	₹46 cr	21.4%	57.0%	0.0x
2020-11	104.6x	₹46 cr	21.4%	57.0%	0.0x
2020-10	136.3x	₹46 cr	21.4%	57.0%	0.0x
2020-09	115.8x	₹46 cr	21.4%	57.0%	0.0x
2020-08	72.4x	₹46 cr	21.4%	57.0%	0.0x
2020-07	40.5x	₹46 cr	21.4%	57.0%	0.0x
2020-06	20.3x	₹46 cr	21.4%	57.0%	0.0x
2020-05	16.9x	₹14 cr	65.2%	—	0.0x
2020-04	11.2x	₹14 cr	65.2%	—	0.0x
2020-03	11.4x	₹14 cr	65.2%	—	0.0x
2020-02	15.7x	₹14 cr	65.2%	—	0.0x
2020-01	12.6x	₹14 cr	65.2%	—	0.0x
2019-12	12.5x	₹14 cr	65.2%	—	0.0x
2019-11	12.0x	₹14 cr	65.2%	—	0.0x
2019-10	12.2x	₹14 cr	65.2%	—	0.0x
2019-09	13.9x	₹14 cr	65.2%	—	0.0x
2019-08	13.4x	₹14 cr	65.2%	—	0.0x
2019-07	10.3x	₹14 cr	65.2%	—	0.0x
2019-06	12.0x	₹14 cr	65.2%	—	0.0x

Methodology and data notes